Milligan, G. , Alvarez-Curto, E. , Hudson, B. D. , Prihandoko, R. and Tobin, A. B. (2017) FFA4/GPR120: pharmacology and therapeutic opportunities. Trends in Pharmacological Sciences, 38(9), pp. 809-821. (doi: 10.1016/j.tips.2017.06.006) (PMID:28734639) (PMCID:PMC5582618)
|
Text
142899.pdf - Published Version Available under License Creative Commons Attribution. 2MB |
Abstract
Free Fatty Acid receptor 4 (FFA4), also known as GPR120, is a G-protein-coupled receptor (GPCR) responsive to long-chain fatty acids that is attracting considerable attention as a potential novel therapeutic target for the treatment of type 2 diabetes mellitus (T2DM). Although no clinical studies have yet been initiated to assess efficacy in this indication, a significant number of primary publications and patents have highlighted the ability of agonists with potency at FFA4 to improve glucose disposition and enhance insulin sensitivity in animal models. However, the distribution pattern of the receptor suggests that targeting FFA4 may also be useful in other conditions, ranging from cancer to lung function. Here, we discuss and contextualise the basis for these ideas and the results to support these conclusions.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | No |
| Glasgow Author(s) Enlighten ID: | Prihandoko, Dr Rudi and Alvarez-Curto, Dr Elisa and Milligan, Professor Graeme and Tobin, Andrew and Hudson, Dr Brian |
| Authors: | Milligan, G., Alvarez-Curto, E., Hudson, B. D., Prihandoko, R., and Tobin, A. B. |
| College/School: | College of Medical Veterinary and Life Sciences > Institute of Molecular Cell and Systems Biology |
| Journal Name: | Trends in Pharmacological Sciences |
| Publisher: | Elsevier |
| ISSN: | 0165-6147 |
| ISSN (Online): | 1873-3735 |
| Published Online: | 19 July 2017 |
| Copyright Holders: | Copyright © 2017 The Authors |
| First Published: | First published in Trends in Pharmacological Sciences 38(9):809-821 |
| Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record
Altmetric
Altmetric